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ABSTRACT
Objectives An investigator-initiated, double-blinded,
placebo-controlled, treat-to-target protocol (Clinical
Trials:NCT00660647) studied whether adalimumab
added to methotrexate and intra-articular triamcinolone
as ﬁrst-line treatment in early rheumatoid arthritis (ERA)
increased the frequency of low disease activity
(DAS28CRP<3.2) at 12 months.
Methods In 14 Danish hospital-based clinics, 180
disease-modifying anti-rheumatic drugs (DMARD)-naïve
ERA patients (<6 months duration) received
methotrexate 7.5 mg/week (increased to 20 mg/week
within 2 months) plus adalimumab 40 mg every other
week (adalimumab-group, n=89) or methotrexate
+placebo-adalimumab (placebo-group, n=91). At all
visits, triamcinolone was injected into swollen joints
(max. four joints/visit). If low disease activity was not
achieved, sulfasalazine 2 g/day and hydroxychloroquine
200 mg/day were added after 3 months, and open-label
biologics after 6–9 months. Efﬁcacy was assessed
primarily on the proportion of patients who reached
treatment target (DAS28CRP<3.2). Secondary endpoints
included DAS28CRP, remission, Health Assessment
Questionnaire (HAQ), EQ-5D and SF-12. Analysis was by
intention-to-treat with last observation carried forward.
Results Baseline characteristics were similar between
groups. In the adalimumab group/placebo group the
12-month cumulative triamcinolone doses were 5.4/
7.0 ml (p=0.08). Triple therapy was applied in 18/27
patients (p=0.17). At 12 months, DAS28CRP<3.2 was
reached in 80%/76% (p=0.65) and DAS28CRP was 2.0
(1.7–5.2) (medians (5th/95th percentile ranges)), versus
2.6 (1.7–4.7) (p=0.009). Remission rates were:
DAS28CRP<2.6: 74%/49%, Clinical Disease Activity
Index≤2.8: 61%/41%, Simpliﬁed Disease Activity
Index<3.3: 57%/37%, European League Against
Rheumatism/American College of Rheumatology
Boolean: 48%/30% (0.0008<p<0.014, number-needed-
to-treat: 4.0–5.4). Twelve months HAQ, SF12PCS and
EQ-5D improvements were most pronounced in the
adalimumab group. Treatments were well tolerated.
Conclusions Adalimumab added to methotrexate and
intra-articular triamcinolone as ﬁrst-line treatment did
not increase the proportion of patients who reached the
DAS28CRP<3.2 treatment target, but improved
DAS28CRP, remission rates, function and quality of life
in DMARD-naïve ERA.
INTRODUCTION
During the past two decades, early and aggressive
treatment of rheumatoid arthritis (RA) with disease-
modifying antirheumatic drugs (DMARD) has sig-
niﬁcantly reduced the effects of the disease in
terms of joint damage and disability.1 Today, remis-
sion is an achievable goal in many patients, irre-
spective of the type of DMARD used, whether
synthetic or biological.2 However, the optimal
treatment strategy in early RA is still debated, and
issues such as initial mono versus combination
therapy and the role of glucocorticoids and biolo-
gics are still disputed.3
In the CIclosporine, MEthorexate and intra-
articular STeroid in early Rheumatoid Arthritis
study (CIMESTRA) study, we reported that aggres-
sive intervention with methotrexate combined with
intra-articular glucocorticoid injections into
swollen joints effectively controlled disease activity
and halted radiographic progression over 5 years of
follow-up in early RA.4–6 This low-cost strategy
yielded results which are comparable with those
reported for biologics as ﬁrst-line therapy.7–12
Thus, it has been speculated that these favourable
results are attributable to a treat-to-target strategy
rather than superiority of any speciﬁc drug.13
The current OPtimised treatment algorithm in
Early Rheumatoid Arthritis (OPERA) study aimed
to investigate whether the results of a CIMESTRA
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strategy using a strict step-up methotrexate protocol combined
with intra-articular glucocorticoids immediately following diag-
nosis with the aim of no swollen joints could be further
improved by adding a tumour necrosis factor inhibitor (TNFi)
as ﬁrst-line therapy. Thus, inﬂammatory control was the aim in
both treatment arms. The proportion of patients achieving
DAS28CRP<3.2 at 12 months was the primary outcome and
DAS28CRP, remission criteria, Health Assessment Questionnaire
(HAQ), EQ-5D and SF-12 were the secondary endpoints.
MATERIALS AND METHODS
From August 2007 through December 2009, 180
DMARD-naïve and steroid-naïve patients with early RA were
recruited consecutively from 14 outpatient clinics at rheumatol-
ogy departments in Denmark and included in the OPERA study.
Patients were aged over 17 years, fulﬁlled the American College
of Rheumatology (ACR) 1987 revised criteria for RA, had a
disease duration (from ﬁrst persistently swollen joint) of less
than 6 months, and moderate to severe RA deﬁned as
DAS28CRP (4 variables, C-reactive protein (CRP)-based)>3.2.
Important exclusion criteria were treatment with glucocorticoids
within the last 4 weeks, previous DMARD therapy, latent
tuberculosis or previous malignancy. A complete list of exclusion
criteria can be found at http://www.clinicaltrials.gov
NCT00660647. Patients were randomised in blocks of four
from a central, computer-generated list of study numbers.
Ethics
All patients gave written informed consent before enrolment. The
protocol was approved by the Danish Medical Agency
(2612-3393), the Danish Data Protection Agency (2007-41-0072)
and the Regional Ethics Committee (VEK-20070008). The trial
was undertaken in accordance with the Declaration of Helsinki,
and carried out according to the principles of the International
Conference on Harmonisation guidelines for Good Clinical
Practice (GCP, 1996 revision) in the European Community under
an independent contract research organisation by the Danish
University GCP units (http://www.gcp-enhed.dk).
Study design and data collection
The OPERA study was an investigator-initiated, randomised,
double-blind, placebo-controlled, two-armed, parallel-group,
multicentre trial.
The patients were randomised into two, double-blinded treat-
ment groups: The ‘adalimumab-group’ started oral methotrex-
ate, 7.5 mg/week at baseline, increased to 15 mg/week after
1 month and 20 mg/week after 2 months (or the highest toler-
ated dose) in combination with adalimumab 40 mg subcutane-
ously every second week. The ‘placebo-group’ received the same
treatment, except that adalimumab was replaced with
placebo-adalimumab.
In both groups, any swollen joint observed at baseline or at a
subsequent visit was injected with triamcinolone hexacetonide
(40 mg/ml, 0.5–2 ml/joint). Up to four joints (max. 4 ml) could
be injected per visit.
The patients were seen at scheduled study visits at baseline, 1,
2, 3, 6, 9 and 12 months. Between the scheduled visits, patients
were contacted by phone (fortnightly the ﬁrst 3 months, every
month thereafter) and interviewed about signs of disease activity
and adverse events, in which case an extra visit was scheduled.
If unacceptable disease activity persisted at the 3 months’ visit
or thereafter, that is, either ‘DAS28CRP≥3.2 and ≥1 swollen
joint’ or ‘intra-articular injection of 4 ml triamcinolone had
been given monthly for 3 consecutive months’,
hydroxychloroquine (200 mg/day) and sulphasalazine (2 g/day)
were added. If the treatment target (low disease activity, see
next section) was not achieved within an additional 3 months,
adalimumab/placebo-adalimumab was discontinued, the patient
was considered a non-responder and excluded from the study,
and open label biologics (other than adalimumab) were pre-
scribed at the discretion of the treating physician. Blinding was
maintained throughout the study period.
The primary outcome was the proportion of patients in each
group that had achieved low disease activity (DAS28CRP<3.2)
at 12 months. Secondary outcomes included DAS28CRP at
12 months, the proportions of patients who at 12 months
achieved: DAS28 remission (DAS28CRP<2.6),14 Clinical
Disease Activity Index (CDAI) remission (CDAI≤2.8),15
Simpliﬁed Disease Activity Index (SDAI) remission
(SDAI<3.3),16 ACR/European League Against Rheumatism
(EULAR) 28/40 Boolean remission,16 and absence of disability
measured by HAQ and Short Form 12-item Survey SF-12v2
Health Survey (S12)-physical component score (PCS).17 18
Other secondary endpoints included quality of life (European
Quality of Life 5 Dimensions (EQ-5D) and SF12-mental compo-
nent score (MCS)). We used a modiﬁed version of EQ-5D with
ﬁve levels of severity and the Danish Scoring algorithm with
linear extrapolation between score dimensions (EQ-5D-5L).19
The cumulative dose of triamcinolone and the number and type
of serious adverse events (SAE) were recorded.
Patient-reported outcomes (HAQ, Visual Analogue Scale
(VAS) for pain, fatigue and global, SF12 and EQ-5D) were col-
lected on touch screens in the waiting room.20 The doctor
recorded number of swollen and tender joints (n=40: metacar-
pophalangeal, proximal-interphalangel, wrists, elbows, shoulder,
knees, metatarsophalangeal and ankle joints), doctor’s global
score (VAS), monitored adverse events, prescribed medication
and gave joint injections. Efforts were made to ensure that the
same doctor followed each patient. CRP was measured using
CRP QUICK-READ (Orion Diagnostica—range 8–160 mg/l).21
All patients received folic acid (5–10 mg/week) and oral calcium
with vitamin D (1.000 mg calcium+800 IU vitamin D daily). At
baseline, treatment with alendronate 70 mg/week was initiated
according to national guidelines. Mild analgesics (acetaminophen)
were allowed, but not non-steroidal anti-inﬂammatory drugs
(NSAID), muscle relaxants or other analgesics.
Statistical analysis
A study size of 180 patients was chosen based on the assump-
tion that 90% of patients in the adalimumab-group and 70% of
patients in the placebo-group would achieve the primary end-
point. A total of 89 patients per treatment arm (dropout ratio
20%) gave 80% power to demonstrate a signiﬁcant (p=0.05)
difference in response rates.
Analysis was by intention-to-treat (ITT). All patients who
received at least one injection with adalimumab or
placebo-adalimumab were included. Last observation carried
forward (LOCF) was applied for patients who withdrew from
the trial before the 12-month visit. In a posthoc analysis, non-
responder imputation (NRI) of the patients who withdrew from
the study was performed for the primary outcome. ITT analysis
without LOCF and completers’ analysis were also performed
and gave similar results (not shown).
Data are presented as medians (5th/95th percentile ranges),
unless otherwise stated. Comparisons between groups were
made with Fisher’s exact test (dichotomous responses) and
Mann–Whitney U test (non-dichotomous). Number-needed-
to-treat (NNT) was calculated for achievement of remission.
Hørslev-Petersen K, et al. Ann Rheum Dis 2014;73:654–661. doi:10.1136/annrheumdis-2012-202735 655
Clinical and epidemiological research
Data were collected in the DANBIO database.22 Data manage-
ment and statistical analysis were done using the R software
package.
RESULTS
Patient characteristics
Baseline characteristics did not differ between the treatment
groups (table 1).
The 12 months’ study period was completed by 161 patients
(89%), and 170 (94%) had a 12-month (ITT) visit. The most
common reasons for withdrawal were patient request/non-
compliance,8 lack of efﬁcacy5 and cancer3 (ﬁgure 1).
Treatment at 12 months
Methotrexate dosage was 20 mg/week (median) in both groups.
There was no difference in the number of visits, including extra
visits. The cumulative dose of triamcinolone and number of
joint injections did not differ between groups. Triple therapy (ie,
adding sulphasalazine and hydroxychloroquine to methotrexate)
was introduced in 18 patients in the adalimumab group and 27
patients in the placebo group (p=0.17) (table 2). Three patients
in the adalimumab group and two patients in the placebo
group were withdrawn from the study due to severe disease
activity and treated with open label biologics (etanercept (3),
inﬂiximab (1), tocilizumab (1)).
Clinical efﬁcacy
Eighty per cent of patients in the adalimumab group and 76%
of patients in the placebo group achieved the primary outcome:
DAS28CRP<3.2 at 12 months (p=0.65) (table 2 and ﬁgure 2).
NRI analysis gave similar results (table 2).
The decline in DAS28CRP from baseline was signiﬁcantly
greater in the adalimumab group throughout the study (ﬁgure
2). At 12 months, the DAS28CRP was 2.0 (1.7–5.2) in the ada-
limumab group versus 2.6 (1.7–4.7) in the placebo group
(p=0.009).
The proportion of patients achieving remission was consist-
ently higher for the adalimumab group than for the placebo
group (ﬁgure 2). The NNTwith adalimumab to achieve remis-
sion in one extra patient was 5.1–8.4 and 4.0–5.4 at 1 and
12 months, respectively, depending on remission criteria used
(table 2). To allow comparison with other studies, the ACR and
EULAR response rates are also shown (table 2).
Median HAQ scores decreased within the ﬁrst month in both
groups and remained low. Thus, after initiation of treatment,
more than 55% of patients in both groups had a HAQ<0.5
Table 1 Baseline demographic, clinical and laboratory characteristics of the study population
Adalimumab group (n=89) Placebo group (n=91) p Value between groups
Age (years) 56.2 (25.8–77.6) 54.2 (28.3–76.7) 0.71
Female sex (%) 63 69 0.46
Disease duration (days) 88 (42–162) 83 (42–150) 0.74
Rheumatoid factor positive (%) 70 74 0.67
Anti-CCP positive (%) 60 70 0.17
Number of tender joints (0–40) 15 (5–38) 16 (6–34) 0.78
Number of swollen joints (0–40) 10 (3–33) 11 (3–31) 0.66
VAS-doctors global (0–100 mm) 57 (27–89) 51 (22–86) 0.10
VAS-pain (0–100 mm) 63 (13–98) 58 (13–92) 0.21
VAS-patient global (0–100 mm) 70 (12–100) 65 (17–96) 0.27
VAS-patient fatigue (0–100 mm) 67 (9–94) 54 (9–92) 0.12
s-CRP (7–161 mg/l) 15 (7–133) 15 (7–109) 0.54
DAS28CRP (1.7–8.7) 5.5 (3.8–7.8) 5.6 (3.8–7.3) 0.53
p Values for differences between two treatment groups by Mann–Whitney U test or Fisher’s exact test.
Anti-CCP, anticyclic citrullinated protein antibodies (in serum); DAS28CRP,Disease Activity Score; s-CRP, serum C-reactive protein; VAS, visual analogue scale.
Figure 1 Flow chart of OPtimised
treatment algorithm in Early
Rheumatoid Arthritis trial; 180 patients
followed for 12 months.
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throughout the study. The decline in HAQ from baseline was
signiﬁcantly greater in the adalimumab group (table 3). A signiﬁ-
cant and sustained increase was observed in both groups in
SF12-MCS within the ﬁrst month but with no signiﬁcant differ-
ences between the groups (table 3). The SF12-PCS and EQ-5D
were signiﬁcantly poorer in the placebo group than in the adali-
mumab group after 12 months (table 3).
Adverse events
SAE were reported in 14 patients in the adalimumab group and
10 patients in the placebo group, including three malignancies
in the adalimumab group: small cell lung carcinoma, myelodys-
plastic syndrome and basocellular carcinoma and two malignan-
cies in the placebo group: urothelial carcinoma and basocellular
carcinoma. Three serious infections were observed in either
group: empyema, pneumonia and bronchitis in the adalimumab
group and pneumonia, bronchitis and dental abscess in the
placebo group. One suspected, but unconﬁrmed infectious arth-
ritis in the adalimumab group was also observed. The remaining
SAE included local subcutaneous atrophy (1), blurred vision (1),
acute myocardial infarction (1), tachycardia (1) and gonarthrosis
(1) in the adalimumab group and ﬁvefold increased serum
alanine aminotransferase (2), disease exacerbation (1), leucopoe-
nia (1), polyneuropathia (1), peptic ulcer (1), coronary bypass
(1), hip fracture (1) and coxarthrosis (1) in the placebo group.
One patient in the placebo group, who terminated the study
due to non-compliance after 6 months, died due to pneumonia
4 months later.
DISCUSSION
Although the proportion of patients who achieved a
DAS28CRP<3.2 response did not differ between the two treat-
ments (80% vs 76%, p=0.65), DAS28CRP was signiﬁcantly
Table 2 Treatment, treatment responses and remission rates after 12 months
Adalimumab-group Placebo-group p Value NNT
Treatment
Methotrexate dosage at 1 year 20 (7.5–20) 20 (11.5–20) 0.24 –
Methotrexate dosage at 1 year (mean(SD)) 18.0 (4.1) 18.6 (3.3) 0.24 –
Number of extra visits/total visits 91/605 111/609 0.23 –
Cumulative triamcinolone dose 0–3 months (ml) 5 (1.8–13) 5.5 (2–12) 0.52 –
Cumulative triamcinolone dose at 1 year (ml) 5.4 (1.8–17.4) 7 (2–18.8) 0.08 –
Number of patients receiving intra-articular injections after baseline visit 79 74 0.63 –
Triple therapy started during the study 20% 30% 0.17 –
Open-label biologics at 1 year 3% 2% 0.98 –
Clinical efficacy after 1 year
Clinical parameters
Tender joint count (0–28) 0 (0–13) 0 (0–9) 0.08 –
Swollen joint count (0–28) 0 (0–6) 0 (0–3) 0.20 –
VAS patient global (0–100) 10 (0–54) 18 (0–69) 0.08 –
VAS patient pain (0–100) 7 (0–64) 20 (0–71) 0.007 –
VAS patient fatigue (0–100) 16 (0–81) 20 (0–84) 0.10 –
VAS doctor’s global (0–100) 1 (0–59) 4 (0–33) 0.03 –
CRP QUICK-READ (7–161) 7 (7–21) 7 (7–44) 0.21 –
Composite disease activity scores
DAS28CRP (1.7–8.7) 2.0 (1.7–5.2) 2.6 (1.7–4.7) 0.009 –
CDAI (0–76) 1.9 (0–27.9) 3.9 (0.1–17.2) 0.01 –
SDAI (0.7–82) 2.7 (0.7–30.4) 5.0 (0.8–20.2) 0.006 –
Treatment target
DAS28CRP<3.2 80% 76% 0.65 –
DAS28CRP<3.2 with NRI analysis 78% 71% 0.44 –
Remission
DAS28CRP<2.6 74% 49% 0.0008 4.0 (2.6–9.1)
CDAI≤2.8 61% 41% 0.008 5.0 (2.9–17.5)
SDAI<3.3 57% 37% 0.007 4.3 (2.6–11.0)
ACR/EULAR 28 joint remission 48% 30% 0.014 5.4 (3.1–22.1)
ACR/EULAR 40 joint remission 47% 26% 0.005 4.8 (2.9–14.5)
Response rates
ACR20 86% 78% 0.21 –
ACR50 80% 63% 0.020 5.9 (3.3–25.8)
ACR70 65% 45% 0.012 5.1 (2.9–18.8)
EULAR good/moderate/none 82/11/7 74/20/7 0.28 –
Values are median, 5th/95th percentile ranges or % of patients. p Values for differences between two treatment groups by Mann–Whitney U test or Fisher’s exact test.
Number-needed-to-treat (NNT): 5/95% CIs (only calculated if p<0.05). CRP, C-reactive protein (serum). Values outside the lower and upper measurement range were set at 7 and 161,
DAS28CRP. Disease Activity Score, 28 joints, CRP based; CDAI, Clinical Disease Activity Index; SDAI, Simplified Disease Activity Index; VAS, Visual Analogue Scale. DMARD, disease
modifying antirheumatic drug; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; NRI, non-responder imputation.
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lower in the adalimumab group throughout the study as com-
pared with the placebo group (table 2, ﬁgure 2).
By contrast, combining adalimumab with methotrexate and
intra-articular glucocorticoid injections as ﬁrst-line therapy in
early RA signiﬁcantly improved the remission rates. In both
groups, adherence to the study protocol was high, and treatments
were well tolerated with no signiﬁcant differences in the use of
methotrexate, intra-articular glucocorticoids or triple therapy.
Figure 2 Black columns: adalimumab group, white columns: placebo group. DAS28CRP and the proportion of patients in each treatment group at
each visit during the 12-month study achieving low disease activity and remission. (A) DAS low disease activity (DAS28CRP<3.2), (B) DAS28CRP,
(C) DAS remission (DAS28CRP<2.6), (D) Clinical Disease Activity Index (CDAI) remission (CDAI≤2.8), (E) Simpliﬁed Disease Activity Index (SDAI)
remission (SDAI<3.3), (F) American College of Rheumatology/European League Against Rheumatism remission (Boolean, 28 joints). **p<0.01,
*p<0.05. p Values for differences between two treatment groups by Mann–Whitney U test or Fisher’s exact test.
Table 3 Disability and health-related quality of life at baseline and 12 months
Adalimumab group Placebo-group p Value between groups
Baseline 12 months 0–12 months Baseline 12 months 0–12 months 12 months 0–12 months
HAQ (0–3) 1.13 (0.17–2.58) 0.25 (0–1.44) −0.88 (−2.46–0.13) 1.00 (0.25–2.31) 0.13 (0–1.5) −0.63 (−1.82–0.38) 0.14 0.012
SF-12 PCS (0–100) 30.9 (13.1–50.6) 49.2 (29.9–56.6) 13.2 (−2.3–33.0) 31.7 (19.3–44.5) 43.3 (26.1–55.8) 10.6 (−11.2–22.7) 0.016 0.015
SF-12 MCS (0–100) 47.0 (28.6–60.6) 55.7 (35.8–62.6) 5.5 (−8.5–20.1) 46.7 (25.7–60.1) 54.8 (40.4–63.7) 4.3 (−9.3–27.4) 0.68 0.83
EQ-5D (0–1) 0.61 (0.17–0.80) 0.82 (0.38–1.00) 0.22 (−0.05–0.67) 0.64 (0.22–0.80) 0.78 (0.49–1.00) 0.20 (−0.06–0.56) 0.04 0.095
Values presented as medians (5th/95th percentile ranges) or % of patients. p Values for differences between two treatment groups by Mann–Whitney U test or Fisher’s exact test.
Baseline values did not differ statistically significant between groups.
DMARD, disease modifying antirheumatic drug; EQ-5D, European quality of life-5 dimensions; HAQ, Health Assessment Questionnaire; SF12 MCS, Short Form 12-item Survey V.2 Health
Survey Mental Component Score; SF12 PCS, Short Form 12-item Survey V.2 Health Survey Physical Component Score.
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In the adalimumab group, 74% were in DAS remission, 61%
in CDAI remission, 57% in SDAI remission, and 48%/47% in
ACR/EULAR Boolean (28/40 joint) remission at 12 months.
Accordingly, we found signiﬁcantly higher ACR50 and ACR70
response rates in the adalimumab group. Compared with the
adalimumab group, the corresponding remission rates for the
placebo group were lower, although very high compared with
other studies (49%, 41%, 37% and 30%/26%, respectively). The
impact of adding adalimumab was reﬂected in a NNT between
4.0 and 5.4 to achieve one additional case of remission after
12 months by adding adalimumab. The remission rates in
the placebo group were higher than those reported in the
CIMESTRA study,5 which may reﬂect an intensiﬁed methotrex-
ate treatment (faster escalation and higher ﬁnal dose) and early
initiation of triple therapy23 if treatment goal was not achieved.
The possible inﬂuence of the shift in intra-articular glucocortic-
oid administered from betamethasone (CIMESTRA) to triamci-
nolone (OPERA) cannot be assessed, but a previous study
indicated a longer-lasting effect of intra-articularly injected triam-
cinolone compared with betamethasone in juvenile arthritis.24
The current OPERA study conﬁrmed that aggressive treatment
with methotrexate at an appropriate dosage (20 mg/week) com-
bined with intra-articular glucocorticoids in any swollen joint
(large or small) and early initiation of triple therapy is highly efﬁ-
cacious in bringing early RA patients into remission.25–27
The beneﬁt of a treat-to-target strategy in early RA including
oral steroids (7.5–10 mg daily with or without higher starting
dose) has been reported in several recent studies.28–32 In the
present study, we chose a different route for the administration
of glucocorticoids by using intra-articular injections, which
might have greater efﬁcacy and fewer side effects than systemic-
ally administered glucocorticoids in RA.33 34 In the CIMESTRA
study, we demonstrated that this approach resulted in low cumu-
lative doses of glucocorticoids and long-lasting remission in the
injected joints.35 In the present study, the cumulative dose corre-
sponded to less than 1 mg prednisolone/day, and less than 5%
of patients received a cumulative dose of triamcinolone corre-
sponding to more than 2 mg prednisolone/day during the study
(assuming that 40 mg of triamcinolone is equivalent to 50 mg of
prednisolone).
Other studies have also reported a superior effect of early
TNFi therapy in treatment-naïve patients with newly diagnosed
RA.7–12 The PREMIER study demonstrated that adalimumab
and methotrexate were superior to adalimumab or methotrexate
alone, resulting in DAS28 remission in 44%, 23% and 21% of
patients, respectively.7 The studies were traditional drug trials
with rather rigid treatment regimes, for instance, not allowing
systematic injection of glucocorticoids into swollen joints. This
may explain, at least in part, why those studies on the one hand
reported greater effects of adding TNFi, but on the other hand,
lower remission rates in both groups compared with the present
study. These trials did not focus on strategy, but rather on drugs.
By contrast, the present study was a strategy trial, aiming to
achieve a low disease activity (DAS28CRP<3.2)13 using a ﬂex-
ible treatment strategy which allowed for dosage adjustments
according to current disease activity.
Three recent studies are similar to ours in relation to study
design, treatment choice and outcome, although they only
allowed ﬁxed oral prednisolone up to 10 mg daily, and zero or
one intra-articular injection during the study.36–38 The
GUEPARD open design study36 compared methotrexate mono-
therapy with methotrexate plus adalimumab for 3 months.
Faster control of disease activity was achieved in the adalimu-
mab group, but no persistent differences were observed,
probably because the study was underpowered due to difﬁculties
in patient recruitment. The randomised, controlled OPTImal
protocol for Methotrexate and Adalimumab combination
therapy in early rheumatoid arthritis (OPTIMA)37 and High
Induction Therapy with Anti-Rheumatic Drugs trial
(HIT-HARD)38 studies compared methotrexate monotherapy
with methotrexate plus adalimumab for the ﬁrst 6 months, and
found that a higher proportion of patients achieved low disease
activity and remission in the combination-therapy group com-
pared with monotherapy. However, the DAS28 remission rates
after 6 months were lower in the OPTIMA (17% in monother-
apy and 34% in the combination-therapy group) and
HIT-HARD (30% and 48%) studies compared with our study
(46% and 62%). This may reﬂect baseline differences in study
groups with slightly higher baseline DAS28 of 6.0–6.2 in the two
studies, compared with 5.6 in the present study, and differences
in the presence of autoantibodies at baseline and in treatment
duration. More likely, the higher remission rates in our study
may reﬂect the consistent use of individualised, intra-articular
glucocorticoid injections in the present study as part of the
treat-to-target strategy. The latter may also explain why—in con-
trast with the OPTIMA study—we did not observe any difference
between groups with respect to achieving low disease activity.
The clinical improvements were reﬂected in near-
normalisation of HAQ, SF-12 and EQ-5D in both treatment
groups, despite signiﬁcantly impaired functional status and
health-related quality of life at the time of study entry.
Normalisation of HAQ was observed within 1 month in the
majority of patients and was maintained thereafter. Compared
with placebo, adalimumab caused a marked and clinically mean-
ingful difference in physical function, as measured by the HAQ,
whereas the changes in SF-12 PCS and EQ-5D were hardly clin-
ically signiﬁcant. There was no consistent effect of adalimumab
on SF-12 MCS. This may reﬂect the fact that SF-12 MCS has
low sensitivity to change.18
It has been suggested that the favourable results in the
CIMESTRA study could, in part, be accounted for by the fre-
quent study visits (15 in 1 year). In the present study, patients
were seen monthly for the ﬁrst 3 months, and then every third
month. This is close to routine care in early RA clinics, and is in
accordance with recommendations of the treat-to-target inter-
national task force.2 There was no difference in the number of
extra visits between the groups (table 2). The safety proﬁles
were good, and the treatments were well tolerated in this early
patient population, with limited comorbidity.
The study has strengths and weaknesses. The double-blinded,
placebo-controlled, prospective design is a signiﬁcant strength.
Furthermore, although many well performed and large rando-
mised clinical trials have been published during the past two
decades, investigator-initiated trials are scarce, and the rigid trial
regimens are seldom applicable to clinical practice. The high
completion rate in our study adds to the statistical strength of
the study. With today’s knowledge, remission may have been
selected as the primary outcome. However, when the trial was
designed, low disease activity was considered a strict target.
This study is the ﬁrst DMARD study in patients with early
RA where NSAID was prohibited. This was decided because
NSAID could potentially blur the recognition of swollen joints.
Patients with persistently tender joints and elevated global pain
scores due to chronic pain comorbidities (eg, osteoarthritis and
ﬁbromyalgia) were eligible for the study and could therefore
theoretically mask response rates.39 However, pain scores
decreased dramatically in both groups, indicating that this was
not a major issue in this population.
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In conclusion, the proportion of patients achieving the prede-
ﬁned treatment target at DAS28CRP<3.2 did not differ
between the two groups. However, combining adalimumab with
an oral methotrexate step-up strategy and intra-articular gluco-
corticoid injections improved DAS28CRP, physical function,
quality of life and remission rates signiﬁcantly throughout the
study period in this investigator-initiated protocol on
DMARD-naïve patients with early RA.
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